-
Mashup Score: 4Earlier breast cancer screening could save ‘20% more lives’ - 15 day(s) ago
Screening earlier and more often could be especially beneficial for Black women, who are 40% more likely to die of breast cancer than white women.
Source: www.newsnationnow.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Earlier breast cancer screening could save ‘20% more lives’ - 15 day(s) ago
Screening earlier and more often could be especially beneficial for Black women, who are 40% more likely to die of breast cancer than white women.
Source: www.newsnationnow.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Earlier breast cancer screening could save ‘20% more lives’ - 19 day(s) ago
Screening earlier and more often could be especially beneficial for Black women, who are 40% more likely to die of breast cancer than white women.
Source: www.newsnationnow.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 163
DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. A statistically significant improvement in progression-free survival (PFS) versus T-DM1 was reported in the primary analysis. Here, we report exploratory efficacy data in patients with and without brain metastases (BMs) at baseline.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9
July 19-20, 2024
Source: www.gotoper.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Sacituzumab govitecan (SG), a first-in-class anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over single-agent chemotherapy (treatment of physician’s choice [TPC]) in patients with metastatic triple-negative breast cancer (mTNBC) in the international, multicenter, phase III ASCENT study. Patients were randomly assigned 1:1 to receive SG or TPC until unacceptable toxicity/progression. Final efficacy secondary end point analyses and post hoc analyses of outcomes stratified by Trop-2 expression and human epidermal gro
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Major Shift in Recommendations for Germline Testing in Breast Cancer - 4 month(s) ago
New breast cancer recommendations call for BRCA1/2 mutation testing in all newly diagnosed patients aged 65 years or younger and certain older patients.
Source: www.obroncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Is Vaccination Approaching a Dangerous Tipping Point? - 5 month(s) ago
This Viewpoint discusses declining vaccination rates in the US, specifically against COVID-19, and the ways in which clinicians and the Food and Drug Administration can counter the current large volume of vaccine misinformation.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, comments on results by age in the Phase III monarchE trial (NCT03155997) of adjuvant abemaciclib combined with endocrine therapy in patients with high-risk early breast cancer. Patients aged 65 years or over had survival outcomes similar to those who are younger. Safety and tolerability were also comparable, and dose reduction is additionally possible, reducing the rate of discontinuation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Analysis of 260K tumors IDs copy-number signatures and a HRD biomarker predictive of PARPi response.
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Thanks to @NicholeBerlie at @NewsNationNowUS for having me talk today about the #USPTF updated breast screening recommendations. Awareness of personal risk factors (including density!) can help you and your doctor formulate the right plan for you! https://t.co/kXLWLrTeUA https://t.co/MYZksgAW9V